SEC Comment Letter for SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491) — Jan 27, 2020
SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491)
Date: Jan. 27, 2020 · CIK: 0001017491 · Accession: 0000000000-20-000681
AI Filing Summary & Sentiment
File numbers found in text: 333-236002
Letter
January 27, 2020 Raj Mehra, Ph.D. President and Chief Executive Officer Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York, NY 10022 Re:Seelos Therapeutics, Inc. Registration Statement on Form S-1 Filed January 22, 2020 File No. 333-236002 Dear Dr. Mehra: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey T. Hartlin, Esq. - Paul Hastings LLP
Show Raw Text
January 27, 2020
Raj Mehra, Ph.D.
President and Chief Executive Officer
Seelos Therapeutics, Inc.
300 Park Avenue, 12th Floor
New York, NY 10022
Re:Seelos Therapeutics, Inc.
Registration Statement on Form S-1
Filed January 22, 2020
File No. 333-236002
Dear Dr. Mehra:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey T. Hartlin, Esq. - Paul Hastings LLP